EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer

Koichiro Yoshino, Manabu Takamatsu, Akira Ooki, Keisho Chin, Daisuke Takahari, Hiroki Osumi, Mariko Ogura, Mikako Tamba, Koshiro Fukuda, Keitaro Shimozaki, Shohei Udagawa, Shota Fukuoka und 3 weitere

Gastric Cancer · 2026

DOI: 10.1007/s10120-026-01736-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2026. Verfasst von Koichiro Yoshino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, Camptothecin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Intratumoral HER2 heterogeneity has been associated with poor response to trastuzumab-based chemotherapy in HER2-positive gastric cancer. However, its clinical significance in patients treated with trastuzumab deruxtecan (T-DXd) remains unclear. METHODS: Patients with advanced HER2-positive gastric cancer who received T-DXd as second-line or later therapy were enrolled. HER2-positive proportion was defined as the percentage of tumor cells with immunohistochemical score ≥ 2 + in diagnostic specimens obtained before first-line therapy. The cutoff value was determined using time-dependent receiver operating characteristic analysis. RESULTS: Forty-three patients were enrolled. Median progression-free survival (PFS) and overall survival (OS) were 4.7 and 8.1 months, respectively. With an optimal cutoff of 79%, 20 patients (47%) were in the HER2-homogeneity group and 23 (53%) in the HER2-heterogeneity group. The HER2-homogeneity group showed significantly longer PFS (6.3 vs. 3.1 months, p = 0.002) and OS (9.8 vs. 6.0 months, p = 0.006) with higher overall response rate (79% vs. 19%, p < 0.001). In Cox proportional hazards model, HER2-homogeneity was an independent prognostic factor for both PFS (hazard ratio (HR) 0.37, 95% confidence interval (CI) 0.18–0.76, p = 0.007) and OS (HR 0.41, 95% CI 0.21–0.82, p = 0.01). CONCLUSIONS: Intratumoral HER2 heterogeneity in pre-treatment diagnostic specimens was associated with T-DXd efficacy and may represent a potential prognostic factor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErb-b2 Receptor Tyrosine KinasesTrastuzumabCamptothecinHumansFemaleMiddle AgedAgedMaleAdultPrognosisSurvival RateFollow-Up StudiesBiomarkers, TumorAntibodies, Monoclonal, HumanizedImmunoconjugates

Stichwörter der Autor:innen

Gastric cancerHER2 heterogeneityPrognostic biomarkerTrastuzumab deruxtecanTrastuzumab-free interval

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humantrastuzumab deruxtecanCamptothecinBiomarkers, TumorAntibodies, Monoclonal, HumanizedImmunoconjugates

Autor:innen und Institutionen

  • Department of Gastrointestinal Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Division of Pathology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Division of Medical Oncology, Department of Internal Medicine, Gunma University Graduate School of Medicine, Gunma, Japan.
  • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan.
  • Department of Gastrointestinal Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. takeru.wakatsuki@jfcr.or.jp.

ORCID-Profile: Takeru Wakatsuki

Zitieren

APA

Yoshino, K., Takamatsu, M., Ooki, A., Chin, K., Takahari, D., Osumi, H., Ogura, M., Tamba, M., Fukuda, K., Shimozaki, K., Udagawa, S., Fukuoka, S., Shinozaki, E., Yamaguchi, K., & Wakatsuki, T. (2026). Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-026-01736-9

Vancouver

Yoshino K, Takamatsu M, Ooki A, Chin K, Takahari D, Osumi H, et al. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer. Gastric Cancer. 2026. doi:10.1007/s10120-026-01736-9

BibTeX
@article{Yoshino2026,
  author = {Yoshino, Koichiro and Takamatsu, Manabu and Ooki, Akira and Chin, Keisho and Takahari, Daisuke and Osumi, Hiroki and Ogura, Mariko and Tamba, Mikako and Fukuda, Koshiro and Shimozaki, Keitaro and Udagawa, Shohei and Fukuoka, Shota and Shinozaki, Eiji and Yamaguchi, Kensei and Wakatsuki, Takeru},
  title = {Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer},
  journal = {Gastric Cancer},
  year = {2026},
  doi = {10.1007/s10120-026-01736-9}
}
Kostenlos starten →